Table 8.
Effect-to-treatment analysis: sensitivity analysis
| No | Study | mST | CA=15% | CA=19.3% | ||||||
| CEST | METR | CNTM | p Value | CEST | METR | CNTM | p Value | |||
| 1 | Brandes153 | 9.95 (7.73–12.17) | 9.64 | 1.20 (0.74–1.95) | 90.98 (48.52 ─ 170.60) | 0.979 | 9.44 | 1.23 (0.75–2.01) | 5.30 (2.97 ─ 9.47) | 0.585 |
| 2 | Strik155 | 8.35 (7.67–9.03) | 7.98 | 0.81 (0.44–1.48) | −2.64 (−5.43 ─ −1.28) | 0.302 | 8.35 | 0.95 (0.49–1.86) | −11.73 (−24.39 ─ −5.64) | 0.830 |
| 3 | Abacioglu156 | 6.98 (6.23–7.73) | 6.98 | 0.57 (0.37–0.89) | −1.62 (−2.94 ─ −0.89) | 0.016 | 6.73 | 0.55 (0.36–0.83) | −2.04 (−3.43 ─ −1.22) | 0.016 |
| 4 | Berrocal157 | 5.60 (4.16–7.04) | 5.35 | 0.19 (0.08–0.49) | −1.00 (−2.77 ─ −0.36) | <0.001 | 5.32 | 0.20 (0.08–0.51) | −1.19 (−3.22 ─ −0.44) | 0.001 |
| 5 | WA (1–4) | 7.27 (6.30–8.24) | 7.07 | 0.59 (0.40–0.88) | −1.68 (−2.93 ─ −0.96) | 0.015 | 6.91 | 0.59 (0.40–0.88) | −2.26 (−3.70 ─ −1.38) | 0.027 |
| 6 | WA (2–4)* | 7.16 (6.25–8.08) | 6.97 | 0.57 (0.39–0.85) | −1.62 (−2.84 ─ −0.92) | 0.011 | 6.82 | 0.57 (0.38–0.85) | −2.14 (−3.52 ─ −1.30) | 0.018 |
| 7 | Sahinbas23 | 7.63 (6.52–8.74) | 9.6 | 1.19 (0.59–2.40) | ∞ | 1.000 | 8.69 | 1.04 (0.77–1.41) | ∞ | 1.000 |
*Main comparator.
CA, coefficient of attenuation; CEST, cost-effective survival time; CNTM, cycles needed to treat per life month gained; METR, median effect-to-treatment ratio; mST, mean survival time; WA, weighted average.